Earnings call transcript Q1 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Hello, and welcome to the PDS Biotechnology First Quarter 2023 Earnings Conference Call and Webcast. [Operator Instructions] A question-and-answer session will follow the formal presentation.

As a reminder, this conference is being recorded.

It's now my pleasure to turn the call over to your host, Gabby DeGravina, Investor Relations. Please go ahead, Gabby.

Gabby DeGravina

to audio first webcast. welcome conference XXXX and and call morning, PDS quarter Biotechnology's earnings Good

Wood, and On Dr. Executive V. Frank call Bedu-Addo, Medical the from Chief Officer; the Dr. Financial Hill, Chief Matt company are Chief Officer. Officer; Lauren

PDS everyone morning, press a will press as The as to the read issued results March XX, PDS release XX well on which ended the PDS be May is Biotech the -- financial Form website Biotech's XXXX. for SEC this press Earlier company's pdsbiotech.com. announcing quarter available with We XX-Q, report the encourage on filed at release shortly. release

call company In conference is addition, the webcast archived website and this reference. will future on be for being

today's regarding will making may as this Before we begin, include and the we of regulatory research United States including in States statements need plans on the other the amended, of forward-looking activities. of as be Act Securities call, to of of concerning United Exchange as statements presentation candidate Act Securities Corporation forward-looking XXXX that remind meaning development and clinical XXA information well Certain matters. and Biotechnology XXXX as within company amended Section PDS Section XXE everyone

to Biotech's subject These can filing description to risks results operations, These that well plans, condition, information are of company's of as operations beliefs and SEC. recent as A discuss or current and PDS intentions management. or assumptions by otherwise differ to most found statements as may trends, and the cause to forecasted. expectations to statements of in be financial goals, made future events, results available based those on currently actual risks may from uncertainties these

reflect on the forward-looking call. to place to speak circumstances. the to by required You subsequent undue undertakes included statements, conference the of of extent no regulation, statements these are update which cautioned applicable Except the date events of PDSB this or obligation not forward-looking to today as law only reliance

now hand call to the Frank. over will I

Frank Bedu-Addo

quarter you Thank today. you, thank Gabby. And first to for joining XXXX call our everyone

be continue about optimistic future the PDS Biotech. We to highly of

a plan as the that candidate for goal our or We advance potential treatment cancer. to develop recurrent cutting-edge first-line therapies Our treatment novel clinical neck and commercialize and HPV is revolutionize to of PDSXXXX metastatic lead positive of have company the significantly cancer. to head

monotherapy, is standard potent targeted cell therapy attack PDSXXXX combination that anti-PD-X We the of a later HPV-positive the will Phase in KEYTRUDA to Merck's studied HPV-targeted against for PDSXXXX cancers. the investigational is a novel this forward care VERSATILE-XXX this X with stimulates which immunotherapy randomized trial, indication. trial year. In be versus KEYTRUDA T initiating look

HPVXX-positive we results of month, trial to a announced and metastatic We for treatment at PDSXXXX the present recently Phase XXXX. for X head first-line recurrent next plan ASCO poster or and abstract cancer. presentation the neck from trial VERSATILE-XXX this of ASCO acceptance updated be our a will interim KEYTRUDA, data At interim that summarizing

discussion. The review expert discussion panel are to on and excited also abstracts say are Thursday, that May selected has We and neck it published during XXth. been scheduled be an head for cancer to

around We'll On host data a to XX:XX press issue our Tuesday, details Eastern Time, presented at to event. call June to this further discuss after presentations, release we at conference X, the announce a.m. plan the ASCO. a

patients is cancer to there address sick neck to continues are of and a rapidly. HPV-targeted The of incidence HPV-positive these the lack therapies of effective very grow disease. Many head and

medical allow advanced cancer. opportunity the to how an ASCO at need PDSXXXX significant neck address us PDSXXXX-targeted head presentation with in clinical provides continue to share with the unmet data the promising and may and scientific us Our community, immunotherapy and to

date, results highlights To X HPVXX-specific with demonstrated T at continue powerful we year, made of types significant this oncology different progress disease the induction all almost to across across have achieving tumor biomarker several stages as pipeline. of milestones PDSXXXX anti-tumor Phase of also PDSXXXX's have tremendous advance we data cancers patients trials XXX activity killer in past We various of clinical cells. at HPV-positive infiltrating and consistent sites. over Substantial XX our

of has its warrants in approved trial. to been in benefit favorable or risk monotherapy a demonstrated activity tolerability profile patients combination controlled whether approximately PDSXXXX with with been a agents. in immune-oncology The delivered investigational of an confirmation PDSXXXX Favorable of XXX has date as chemo-radiotherapy registrational to standard care

the discuss let's the of details trial. VERSATILE-XXX Now,

required transfer, During X the a activities global and first scale multi quarter, we manufacturing we center completed tech initiate up key Phase trial. to announced that registrational

conversations continued third on an Administration, We IND to and submit the design. regulatory the to affirm U.S. VERSATILE-XXX also awaiting investigational have European feedback the quarter Food study or plan amendment drug Drug our new in or are agencies XXXX. the We and FDA, with their of

with KEYTRUDA monotherapy sites enroll as KEYTRUDA are We survival, with The approximately will endpoints trial comparator arm survival, or PDSXXXX active primary and with XXX XX PFS. controlled registrational clinical X:X Phase conduct as overall XXX to X the combination to randomize or and trial globally, arm. intend in to progression-free and OS, The a subjects the at individuals.

regarding of may for FDA early significant with trial quarter this Additionally, discussion be approval. that we there two fourth the to milestone in the look of this interim anticipate and opportunities will year. planned Biotech analysis accelerated the VERSATILE-XXX Initiation trial forward a starting provide PDS is we for

an and our has used list a promising anal, in in ICI tumor our PDSXXXX, of in X investigational is This and including cancers in both. Phase ICI and head both highly on inhibitor, demonstrated triple commercial types evaluated IL-XX investigational survival PDSXXXX, our naive responses and vaginal targeting Also combination of cervical, vulvar priority a HPV-positive been cancers combination all checkpoint cancers, neck, refractory commercialization ICI ICI. immune with novel in trial and penile, benefit or clinical objective

We work meeting successful published FDA with program. the done the for by develop understand the Phase Cancer the extensive the results a preclinical results the corroborated next National to steps to Institute The X announced combination. discuss of and

head As of we this and last neck plan the ICI the in markets. growing and refractory cancer, to first cancer largest HPV rapidly reported, we commercialize most combination

essential the registrational triple indication study. the to We, with exact will trial design the the and the combination. initial in the data of quarter registrational year. us it arm the is study, PDSXXXX neck of refractory the study This inform obtain data combination of of the from of we for treating before we refractory evaluating head from third To the in potential of ICI believe be population patients therefore, is VERSATILE-XXX KEYTRUDA during design that the anticipate cancer VERSATILE-XXX and this the finalizing

provide We and to near will be the the update able results future. hopefully on in an clinical design

designated immune-oncology and announced Last opinion cytokine PDSXXXX. discussion National novel month, Dr. our our The Jeffrey experts, of Merck included second the conjugated Institute therapy. key of IL-XX, Dr. Last antibody Schlom. KGaA's quarter, IL-XX some KOL, Cancer we James now we PDSXXXX potential which limitations highlighted leader, roundtable discussion. hosted overcome current acquisition The focused of of to Gulley on the discussion

the visible tumor the the promoting simple targeting injection, T targeting subcutaneous and benefits. more IL-XX to T IL-XX the is hot, potential and current target By to within and slide, cells, make the able antitumor after as IL-XX tumor. making seen tumors termed infiltration and tumors also is the a activation to the in to promoting tumors Unlike the traditional areas simultaneously IL-XX of while cell brings the blood. the The to antibody IL-XX enhance the limits presence utilizes IL-XX, tumor in antibody PDSXXXX, in an IL-XX's safety antibody results its to necrosis. This into in conjugated

Cancer that plot, Dr. last combination again radiation. using demonstrating, preclinical the I lung the or the of Institute. radiation some month. of the review in Schlom Examples highlighted event National HDAC, we studies reduction these some In would PDSXXXX first are Dr. that plot, ongoing inhibitor. during tumor resistant Gulley and of the of the were the Schlom of resistant to of like the and Gulley ICI trials significant is of with a slide combination at of the second treatment deacetylase, shown highlighted current the on KOL and see PDSXXXX promising eradication results by established the histone to some tumors and inhibitor cancer investigator-initiated

discussed Phase PDS are solid of the studies gallbladder others. sarcoma combination number kaposi and standard X care investigator-initiated PDSXXXX these promising of the Institute. a among ongoing are including tumors, being of X National Institute of preclinical Based as Biotech's Four Phase Cancer collaborative in there during colon, under and number National agreement with in research these a cancer, on KOL prostate, studies event, Cancer performed with studies, development

been has XXX PDSXXXX to generally combination with administered been tolerated in date, has well patients and over other cancer treatments. even To

being are additional to Biotech. that no like PDS emphasize studies would cost I Now, performed to at these

summary. call, to like the to call of Matt? Matt and the portion discuss concludes That hand the my financial to over I'd

Matt Hill

you, Frank. Thank

now Let's financial XXXX. the results for at XX, our look March months three ended

costs months three quarter share diluted XXXX, personnel the affairs medical per higher basic for The studies net same XX, for per or and loss $X.XX ended net million costs, expenses. $X.X $X.XX $X.X diluted the loss of this a compared basic to and share, Net of to clinical period and or XXXX. loss was was March million approximately due

and $XXX,XXX about and ended $XXX,XXX of expenses was professional in The $XXX,XXX $X.X in fees, manufacturing by approximately to in to primarily quarter March medical costs $XXX,XXX studies increased decrease attributable months for XXXX. development million XX, a to $XXX,XXX an the XX, of approximately personnel XXXX Research increase $X.X the costs. and three of in clinical for compared affairs, March million ended offset increase

quarter of was increase costs, a increase for million professional compared $X.X period attributable fees. expenses General an million for The offset increased to which to approximately XXXX. the primarily and personnel slightly the in was by $X.X to of $XXX,XXX in decrease administrative of first same $XXX,XXX XXXX $XXX,XXX of

of XXXX. million expenses the ended $X.X months operating XXXX for quarter $X.X were the to three XX, approximately March expenses March operating XX, million approximately a ended Total total compared for

of monetized Technology New unrelated to to New Tax Net Jersey Certificate In loss carry pursuant state to net our forwards the benefits April, operating tax of Transfer in in year New Jersey for the the receiving tax Jersey $X.X Business participation company's sale Loss Corporation Operating an million profitable the Program net we the XXXX.

prudent in-license trials We was discipline like would execution result the to company. continuous of payment $X with ended that a PDSXXXX efficient financial no the of PDSXXXX and investigator-initiated $XX.X cost impacted at on KGaA and for burn million are reiterate cash cash. our million the as Merck to quarter incremental our I ATM. the The our to approximately of in

balance Our we cash as XXXX. into will company operations well quarter programs, of development believe, the as research and fund the third

would session. Q&A Operator? operator the completes the call back this discussion. for financial like the to hand I at And This time, my to

Operator

you. Thank

Fitzgerald. conducting question We is first Instructions] from a Chen now Cantor Our [Operator will be question-and-answer from coming Louise session.

live. now is line Your

Louise Chen

Hi. my taking Thanks questions for here.

to So, around ask interim X color analysis? your wanted I potential first Can looking how the Phase the you interim give more analysis, at VERSATILE-XXX. on study, timing you on you're the the

then, to on XXX? if secondly, presenting going that your at can more VERSATILE-XXX expert what thoughts in other the ASCO data addition panel you to ASCO? at And review provide And you will be? are study And so, that's

last expenses question do through then in fact about of the remainder to we light going R&D how just and is this And study? Thank you're especially SG&A Phase think X you. of year, start the the

Frank Bedu-Addo

Louise. expert session, SG&A. hand the over Lauren neck and and discuss and head Matt answer your I'll cancer of then I'll Thank the part the to to then you, discuss first at question, to the panel to

how Louise, question, we're we're and interim your of to trial of had part with around looking those at some the first data how the points. do data the designing interim So,

even mentioned, interim I here interim data that study is as to as to the we as at well survival survival. design So, are statistical the for the be the The so -- be robust to data statistics statistical meaningful. trial going goal progression-free points. endpoints What the for have we're looking overall is around

to OS. a are of those put at significant specific as So will the interim looking data as make readout points place or the the robustness the right? for strong for give of us both be And we're a number final interim overall point just statistics. the data that OS final then, And will interim first in will well readout, PFS so second sure be patients around PFS survival. course, that point And the and data be would

from by the we go the those study have have to also anticipate also VERSATILE-XXX of we around and be be that discussions with what up also we completed would that will the data FDA, the study time those But updating, we'll interim what any results. to discussing back

panel the hand ASCO conference. to discuss And Lauren, I will to at you over the

Lauren V. Wood

your for Louise, Frank, Thanks, Yes. thanks, question. and

following several Monday approaches session presented will be panel of discussion and abstracts. but by poster June poster X, the the the poster and head be an there VERSATILE-XXX, at this looking data presented that's the to will be only other several of poster So presentation of our afternoon, poster discussion, on specific And will cancer. ASCO panel. a not there be and at points the members expert head treatment neck held during discussion of will The of assessment neck that of

We're this, all an excited opportunity during for of are this challenging of as presented meeting in that of context of population. the discussion about approaches treatment very is it well awareness for being because as greater the of VERSATILE-XXX potential the the

Frank Bedu-Addo

from be Mayo add Clinic the Lauren, VERSATILE-XXX will study. PDS I'll to Katharine that presenting Dr. that, Price

Lauren V. Wood

That is correct.

Frank Bedu-Addo

the you to over SG&A. Okay. Matt, hand we'll for

Matt Hill

Louise, Thanks, great Frank. question.

associated envision respect our what cash to the we is cash in to associated to on expense, to Is going primarily. about is primarily except -- that for What that burn. up with expect essentially, million We forward million. company. is That's our to steadily Louise, in this until be comp you expenses, So, a about administrative you to R&D ramp get burn -- to -- costs, helpful? increase $XX quarter we million going we will that manage with need significant that -- non-cash in increases $X projections quarter add that the $XX what will be with stock which ran don't

Louise Chen

$XX the $XX $XX to -- that if on the to the saying million million going you kind of Is add plan GAAP $XX achieve on Yes, a it's million $X million, quarter? fourth by be? like you're it what does. million say, burn it's that And this basis? And then to you to so

Matt Hill

Yes, quarter by there that year. up of fourth third -- we'll and this probably get

Louise Chen

you. Thank Okay.

Operator

Thank you.

Leland from coming from is question next Oppenheimer. Our Gershell

live. is Your line now

Leland Gershell

questions. few you from the questions for Thank my taking updates me. A and

expect on data? established again, analyses, expect have kind garner interim to so Just you with -- potentially criteria you accelerated discussion to sorry, when the respect or planned with the those with allow could FDA agency do the you that what a with VERSATILE-XXX approval, of Versamune respect to would to have be to you

to awaiting any there as we patients? population, VERSATILE-XXX, in a see Second, be combination a be there may there may KEYTRUDA but addition triple ICI to from combo road with refractory us you as could possibility the we're that as the what plus PDSXXXX doublet, for -- still data the down that benefit explore is the in those chance for

event the you. And recent Entinostat then data the with if to combination of work finally, promising. at that with thoughts quite inhibitors. inspired trial any respect clinical reviewed looked HDAC Thank that's wondering were the I'm

Frank Bedu-Addo

lot Leland, for thanks a those questions.

accelerated commitments for based on know, not It's and starting and whether and and product the be have trial discussed wait data acceptable approved see right? the "Let's or that make interim we've discussion," So the or with those whether VERSATILE-XXX points will not as they'll be a interim you FDA will always, FDA, or accelerated to not with approval results. whether the

FDA this at make statistical ourselves sure potentially So the patients we to in points with design interim to give that have have discussion the VERSATILE-XXX those that robust opportunity is positive have that good that that with enough approached designed we in way data is just a together really point. a the the results we enough

reviewing However, our mention protocols. FDA I will that is also the currently

IND. the we So our to protocol FDA review the before file actually did agree amended

alignment before it, we're So have taking the at we the start will least, hopefully. FDA on with we some approach

number patient trial, we high clear PDSXXXX, to performed dose. population, impact mentioned And checkpoint benefit which as as is VERSATILE-XXX PDSXXXX that low inhibitor dose of moving the think are a to The the saw combination a checkpoint at specifically, indicating triple were of together We KEYTRUDA the I in in our National tumor-targeted forward that refractory population the IL-XX. refractory in times, very Cancer with of then versus inhibitor that terms studies committed we've relates were plus as it of the the right? Institute IL-XX in patient

role was in specific of And clear IL-XX patients. is those so the what it

what whether information versus at However, that plus of doublet population. rather how that we're to move statistical the we understand right? determine not will That forward design in doublet trial, to PDSXXXX on but how we that give finalize the in is KEYTRUDA triple, patient the looking is specific performing us that

the So or let have potentially care -- what versus us today. could standard we right? understand exactly delta how much buffer of

to make sure of is data. we've and taken we pertains all to to believe providing just -- significant important very sure And ourselves may the we our information that reason. we've trials we us make to shareholders that owe done extracted just go a We one very that we've into design trials and trial. want all to how actually with that these these and Each a that for

are that So should we what we triple that that -- what inform to the study. survival, doublet with the a example? to the So is, seen from based doublet we going providing does we what statistical overall combination? has endpoint patients saw compare we've versus for upon obtaining those really How that that's really design with portion improved how the it's trial seen are of triplet, And with how just we've what design right?

HDAC couple approved. a the is are is ongoing one benefits clinical inhibitors this the as was of them FDA that studies with the generated of And the HDAC data at the third Cancer you inhibitor Institute and in extremely I is know, And X question around Cancer the you as the one currently National Institute mentioned, Phase inhibitors. the HDAC study preclinical Yes, the that -- trials at promising. asked already of was the that National with the

commercial perform inhibitors. FDA-approved HDAC those in or actually we So, HDAC studies can

the the so the and of studies by PDSXXXX correct additional inhibitors, is these provided ongoing preclinical promising. that's for And the PDS, the HDAC are to PDS. they you that are far cost data combination no performed benefit But at NCI been being are with of extremely also

that also potential a we of So our as number with get studies done we've also. PDSXXXX benefit

hope I Leland, this questions. your answered

Leland Gershell

No, it Thank you. did. Yes.

forward Looking ASCO. to

Frank Bedu-Addo

a Thanks lot.

Operator

you. Thank

from Securities. B. today question is Patel Next Riley from coming Kalpit

live. line is now Your

Andy Fleszar

sense patients' A data morning. the you anticipating or you for Thank on OS Good expect? of results mature on you study? updated question. are taking how should for to XX-month ASCO. Kalpit. us Fleszar many to the the This Andy present be at Can VERSATILE-XXX OS for data you couple a from from us And is worth enough of give median

Frank Bedu-Addo

So Andy, and Today, the number the trial abstracts on made the thanks I'll talk think, hand lot first for portion of that been XX. a are public, question. Lauren. over yet. The about patients I'll we hasn't will be as I that to in public the May of part, said,

we where information size that all and number of will trial XX. of So public on become all regarding today, patients are the May so the forth

Lauren, to is there anything you want that? to add

Lauren V. Wood

just data nine-month had where was of No, nine will XX that population the we last rates we June in update year, XX% presented months. PFS be subjects, our initial at in survival and overall to of that rates looking of

specific on data the a be May population be in will duration out monitoring, and the a that longer larger details So for of comes that release XX. updated will in

Andy Fleszar

before work amended IND you. needs Phase filing performed? an X. And then the to successfully key XXX It what the CMC-related Thank for been one Okay. be still third in are bottlenecks sounds And the quarter? has What manufactured follow-up. like

Frank Bedu-Addo

quarter, as So, potential our from manufacturer the traditional last I our characterization on transferred think, commercial clinical our to process manufacturing, the mentioned, to some so of related manufacturing manufacturer. we I

you by that successfully has transfer product scale had we've as Phase we correct, X manufacturer so, up. been And tech And as the manufactured are released. this now well successfully go and clinical through to

of One key is to package reflect the have manufacturing we CMC the do things the to new to process. change

changes scale So, those there Or transfer change to is why that product, scale, as the do might be are important be in in one tech a that slightly the make some of to processes machinery very effectively the right? you slightly, right? package. of properly reflected small the that large go mixes it's from reasons So detailed have CMC different to in to those may used a

The manufacturer, move methods release you are utilized analytical be that other product the right? is, new critical the to the to as validated, have thing to

year. are mentioned, to this are doing get things file looking think, those as to quarter of thing in currently the we're some last I done. So IND quarter, the on this the to able that And I third track we're be of

So for file before those material right, manufacturing months properly to the stability characterizing released. properly the process, example, we the CMC we of really a is characterizing have The processes, certain and have release stability related to actually IND. program, how the activities of number

filing activities QX. track all are that the CMC and those So, on are in currently which ongoing still IND for

Andy Fleszar

taking I additional color. you appreciate the Thank questions. the for

Frank Bedu-Addo

No problem. a lot. Thanks

Operator

Instructions] [Operator question from Noble next Capital you. Thank LeBoyer coming is Robert Markets. Our from

Your line is now live.

Robert LeBoyer

of give any number when you terms in any calendar as or to or be of to Thank in guidance events, you. an to trial, the when a timing VERSATILE Can or them? the going whether of whether get the us criteria it's these expect expected be in it's to will or of else trial idea by analysis on enrollment, progression, anything interim triggered the

Frank Bedu-Addo

before we awaiting start want going FDA. We has are make the that in making trial from of course. -- that of regarding Currently, those Yes, FDA blessed timelines. due to the those think the feedback public I detail to time some we'll sure some we make

the We've in upon will designing anticipate enrollment rates we with we the VERSATILE-XXX, this thing's the we as FDA rates. are have let's right? observed alignment observed really First later quarter. get first, good based have some recruitment But we that trial

based upon and public. results the made we've already we're trial currently sites results in Phase We the the have programs many seeing the interested with extremely that X

to we've least we And be at with enrollment rates meet will exceed that that VERSATILE-XXX. so, or we are able seen hopeful

are we looking As I XX mentioned, to globally. at XXX sites

the performance really and in were But will those facilitate we sites the speed this once due make -- reasons here up one we finalize large hopefully, public course of is been number So, once to of of IND trial. a submitted. has successfully enrollment key

Robert LeBoyer

question. Okay. That also my answers second

-- thank questions, the the progress. So, for for on taking you all the and congratulations

Frank Bedu-Addo

much. very Thank you

Operator

Thank you.

is Molloy question Next from Global coming Partners. today Alliance from James

Your line now live. is

James Molloy

Hey, guys. the little quarter bit as for data you or with are questions. characterize going? the triple talk waiting still Thanks partnership guys you a are combo, past in an in how You've about where update here 'XX? good discussions data, stand? we XXX fourth Have the And for talked of of And then, morning, partnership on or the (ph) or could given my ASCO anticipating do taking things [bintra] partnerships VERSATILE. the much the this do currently? see And environment how you

Frank Bedu-Addo

Thanks a lot, James.

triple first the triple already combination, we've the the survival median as know, the you So, question related part mentioned the overall combination, for population. of to -- refractory this the

in population, think year, of that last at in were the the XX alive. we mentioned naive readout the still However, patients last I XX% with demonstrated of -- QX months, the

median yet months, not we survival. overall at the reached XX have So

an on this that next expect population, year, quarter CPI-naive survival sometime particular the in update quarter, this patient be there or we the So, hopefully, will patients. that

tracked followed. that those So patients still are being -- and

inhibitor. triple we'll potentially to the with So update commercial checkpoint the trial registrational be And could bintra be moving that switching from into as Phase away trial, for -- bintra. you from a will we the have know, the X combination

the with discussions partnering And ongoing. are partnering,

these forward. opportunistic programs know, for some look have As move you as been and potential we how of we extremely partners we

X key want commercialized often into registrational product go a trial. Very that you'll potential Phase what of things and your you discussions, that successfully is the through how those X. Phase facilitates Phase know, progression the to the partners potential protocol is know prospective One that and is X to be going as and

also significant one So, the may are discussions development with here we in prospective progress areas that you as of business and be PDS those helping But key focus where today. of to know, some is at today facilitating is those discussions we of having partners.

those so as may prospective are expect, And with partners. progressing discussions, you

James Molloy

Great. questions. taking Thank you the for

Operator

I'd the further comments. back our like floor session. closing end reached Thank turn over you. We any question-and-answer the for to of or

Frank Bedu-Addo

Thank you very much.

all, earnings to appreciate joining you So, first really today's call. XXXX quarter we conference

with the pleased have made quarter. this extremely are we We progress

excited PDSXXXX. milestones We for to on you update We candidate, look this be to especially continue year, our forward lead our upcoming clinical about continuing our progress. to

I you a you great very all week, and much. thank wish

Operator

conclude you. today's teleconference webcast. does and Thank That

You may for you time, disconnect wonderful your a today. your and this have day. line at participation We thank

PDS Biotechnology (PDSB) 15 May 232023 Q1 Earnings call transcript